Hospital-Acquired Bacterial Pneumonia (HABP) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Hospital-Acquired Bacterial Pneumonia Emerging Therapy and TPP Insights

Thelansis’s “Hospital-Acquired Bacterial Pneumonia (HABP) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Hospital-Acquired Bacterial Pneumonia Overview

Hospital-acquired bacterial pneumonia (HABP) develops 48 hours or more after admission and was not present at admission. It affects non-ventilated patients; ventilator-associated pneumonia is a related, distinct entity. Pathogens include Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacterales, and Acinetobacter; multidrug resistance is not universal. Symptoms include fever, purulent sputum, new infiltrates, worsening oxygenation, or sepsis. Diagnosis combines clinical assessment, imaging, and respiratory cultures. Empiric antibiotics are selected using severity, prior microbiology, resistance risks, and local antibiograms, then narrowed when results return. Cefiderocol treats susceptible Gram-negative pathogens; sulbactam-durlobactam targets susceptible Acinetobacter baumannii-calcoaceticus complex. Supportive care and source control may be required. Resistance and drug toxicity complicate care, underscoring rapid diagnostics and antimicrobial stewardship.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)